BRIEF—Jiangsu Hengrui out-licenses asthma drug rights to ONEBIO

Chinese pharma company Jiangsu Hengrui Pharmaceuticals has granted USA-based ONEBIO exclusive rights to its anti-TSLP monoclonal antibody SHR-1905 in a deal covering everywhere except China.

The deal is worth $21.5 million upfront and potentially more than $1 billion in development and sales milestones if the drug is approved in the USA, Japan and certain European countries.

SHR-1905 is a monoclonal antibody injection used in the treatment of severe asthma. It is currently in Phase II trials for asthma and chronic sinusitis.